Early results from a phase II clinical trial show that the third-generation tyrosine kinase inhibitor ponatinib plus the bispecific T-cell engager blinatumomab can produce complete molecular remissions in most patients with Philadelphia chromosome–positive acute lymphoblastic leukemia.

©2021 American Association for Cancer Research.
2021
American Association for Cancer Research.
You do not currently have access to this content.